| Ytd | 9.54% | |
| 1y | -28.77% |
| Open | 6.50 | Prev Close | 6.58 | Low | 6.50 | High | 6.68 | Mkt Cap | 160.90M |
| Vol | 149.59K | Avg Vol | 350.18K | EPS | -0.69 | P/E | -9.65 | Forward P/E | -5.96 |
| Beta | 1.35 | Short Ratio | 3.12 | Inst. Own | 57.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 4.85 | 200-d Avg | 5.02 | 1yr Est | 6.25 |
XGN News
Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, averag
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular se
Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estim
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday'
Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly
CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers D
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Ex
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as ex
Exagen Inc. (XGN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estim
CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider o
Exagen Inc. (NASDAQ: XGN - Get Free Report) has been given an average recommendation of "Moderate Bu
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Exagen Inc. (XGN) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus
Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force e
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the
CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider o
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its